Asymptomatic Primary Hyperparathyroidism

Journal of Clinical Densitometry

Volumn 16, Issue 1, 2013, Pages 14-21

  Silverberg, Shonni J ^a   Walker, Marcella D ^a   Bilezikian, John P ^a  

^a College of Physicians and Surgeons Columbia University ^*  (United States)

Author keywords

Asymptomatic primary hyperparathyroidism; Normocalcemic primary hyperparathyroidism; Parathyroidectomy

Indexed keywords

CINACALCET;

ARTICLE; ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; DEMOGRAPHY; DIFFERENTIAL DIAGNOSIS; HORMONAL THERAPY; HUMAN; MUSCLE DISEASE; NEUROMUSCULAR DISEASE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PSYCHOLOGY; SKELETAL MUSCLE; TREATMENT INDICATION; TREATMENT OUTCOME;

ASYMPTOMATIC DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERPARATHYROIDISM, PRIMARY; NAPHTHALENES; OSTEITIS FIBROSA CYSTICA; PARATHYROID HORMONE;

EID: 84873113348     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2012.11.005     Document Type: Article

References (81)

1. Albright F., Aub J.C., Bauer W. Hyperparathyroidism: a common and polymorphic condition as illustrated by seventeen proved cases from one clinic. JAMA 1934, 102:1276-1287.
2. Heath H., Hodgson S.F., Kennedy M.A. Primary hyperparathyroidism: incidence, morbidity, and economic impact in a community. N Engl J Med 1980, 302:189-193.
3. Silverberg S.J., Bilezikian J.P. The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab 2006, 2(9):494-503.
4. Eastell R., Arnold A., Brandi M.L., et al. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009, 94(2):340-350.
5. Bilezikian J.P., Mulder J.E., Silverberg S.J. Hypercalcemic states: differential diagnosis and acute management. Disorders of Bone and Mineral Metabolism 2008, Lippincott, Williams & Wilkins, Philadelphia, PA. 2nd ed. F.L. Coe, M.J. Favus (Eds.).
6. Fuleihan Gel.-H. Familial benign hypocalciuric hypercalcemia. J Bone Miner Res 2002, 17(Suppl 2):N51-N56.
7. Endres D.B., Villanueva R., Sharp C.F., Singer F.R. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 1991, 37:162-168.
8. Nussbaum S.R., Zahradnik R.J., Lavigne J.R., et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987, 33:1364-1367.
9. Silverberg S.J., Brown I., LoGerfo P., et al. Clinical utility of an immunoradiometric assay for whole PTH (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88(10):4725-4730.
10. Silverberg S.J., Lewiecki E.M., Mosekilde L., et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009, 94:351-365.
11. Bilezikian J.P., Silverberg S.J. Clinical practice: asymptomatic primary hyperparathyroidism. N Engl J Med 2004, 350(17):1746-1751.
12. Silverberg S.J., Shane E., Dempster D.W., Bilezikian J.P. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 1999, 107(6):561-567.
13. Boudou P., Ibrahim F., Cormier C., et al. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 2006, 29(6):511-515.
14. Broadus A.E., Horst R.L., Lang R., et al. The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Engl J Med 1980, 302:421-426.
15. Silverberg S.J., Shane E., de la Cruz L., et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989, 4(3):283-291.
16. Eriksen E.F. Primary hyperparathyroidism: lessons from bone histomorphometry. J Bone Miner Res 2002, 17(Suppl 2):N95-N97.
17. Dempster D.W., Müller R., Zhou H., et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 2007, 41(1):19-24.
18. Stein E.M., Dempster D.W., Udesky J., et al. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone 2011, 48(3):557-561.
19. Dauphine R.T., Riggs B.L., Scholz D.A. Back pain and vertebral crush fractures: an unemphasized mode of presentation for primary hyperparathyroidism. Ann Intern Med 1975, 83:365-367.
20. Wilson R.J., Rao S., Ellis B., et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988, 109:959-962.
21. Larsson K., Ljunghall S., Krusemo U.B., et al. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med 1993, 234:585-593.
22. Kenny A.M., MacGillivray D.C., Pilbeam C.C., et al. Fracture incidence in postmenopausal women with primary hyperparathyroidism. Surgery 1995, 118:109-114.
23. Khosla S., Melton L.J., Wermers R.A., et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999, 14:1700-1707.
24. Vignali E., Viccica G., Diacinti D., et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94(7):2306-2312.
25. Vestergaard P., Mollerup C.L., Frøkjaer V.G., et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000, 321:598-602.
26. Khosla S., Melton J. Fracture risk in primary hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl 2):N103-N107.
27. Walker M.D., Dempster D.W., McMahon D.J., et al. Effect of renal function on skeletal health in primary hyperparathyroidism. J Clin Endocrinol Metab 2012, 97(5):1501-1507.
28. Patten B.M., Bilezikian J.P., Mallette L.E., et al. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med 1974, 80:182-193.
29. Turken S.A., Cafferty M., Silverberg S.J., et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med 1989, 87:553-557.
30. Silverberg S.J., Walker M.D., Bilezikian J.P. Asymptomatic primary hyperparathyroidism. J Clin Densitom 2013, 16:14-21.
31. Prager G., Kalaschek A., Kaczirek K., et al. Parathyroidectomy improves concentration and retentiveness in patients with primary hyperparathyroidism. Surgery 2002, 132(6):930-935.
32. Roman S.A., Sosa J.A., Mayes L., et al. Parathyroidectomy improves neurocognitive deficits in patients with primary hyperparathyroidism. Surgery 2005, 138(6):1121-1128.
33. Chiang C.Y., Andrewes D.G., Anderson D., et al. A controlled, prospective study of neuropsychological outcomes post parathyroidectomy in primary hyperparathyroid patients. Clin Endocrinol (Oxf) 2005, 62(1):99-104.
34. Benge J.F., Perrier N.D., Massman P.J., et al. Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy. J Int Neuropsychol Soc 2009, 15(6):1002-1011.
35. Walker M.D., McMahon D.J., Inabnet W.B., et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 2009, 94(6):1951-1958.
36. Roman S.A., Sosa J.A., Pietrzak R.H., et al. The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann Surg 2011, 253(1):131-137.
37. Perrier N.D., Balachandran D., Wefel J.S., et al. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery 2009, 146(6):1116-1122.
38. Brown G.G., Preisman R.C., Kleerekoper M. Neurobehavioral symptoms in mild primary hyperparathyroidism: related to hypercalcemia but not improved by parathyroidectomy. Henry Ford Hosp Med J 1987, 35(4):211-215.
39. Solomon B.L., Schaaf M., Smallridge R.C. Psychologic symptoms before and after parathyroid surgery. Am J Med 1994, 96(2):101-106.
40. Espiritu R.P., Kearns A.E., Vickers K.S. Depression in primary hyperparathyroidism: prevalence and benefit of surgery. J Clin Endocrinol Metab 2011, 96(11):E1737-E1745.
41. Pasieka J.L., Parsons L.L., Demeure M.J., et al. Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg 2002, 26(8):942-949.
42. Sheldon D.G., Lee F.T., Neil N.J., Ryan J.A. Surgical treatment of hyperparathyroidism improves health-related quality of life. Arch Surg 2002, 137(9):1022-1026. discussion 1026-1028.
43. Quiros R.M., Alef M.J., Wilhelm S.M., et al. Health-related quality of life in hyperparathyroidism measurably improves after parathyroidectomy. Surgery 2003, 134(4):675-681. discussion 681-683.
44. Amstrup A.K., Rejnmark L., Mosekilde L. Patients with surgically cured primary hyperparathyroidism have a reduced quality of life compared with population-based healthy sex-, age-, and season-matched controls. Eur J Endocrinol 2011, 165(5):753-760.
45. Rao D.S., Phillips E.R., Divine G.W., Talpos G.B. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004, 89(11):5415-5422.
46. Bollerslev J., Jansson S., Mollerup C.L., et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007, 92(5):1687-1692.
47. Ambrogini E., Cetani F., Cianferotti L., et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007, 92(8):3114-3121.
48. Nilsson I.L., Yin L., Lundgren E., et al. Clinical presentation of primary hyperparathyroidism in Europe-nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002, 17(Suppl 2):N68-N74.
49. Ogard C.G., Engholm G., Almdal T.P., Vestergaard H. Increased mortality in patients hospitalized with primary hyperparathyroidism during the period 1977-1993 in Denmark. World J Surg 2004, 28(1):108-111.
50. Wermers R.A., Khosla S., Atkinson E.J., et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998, 104(2):115-122.
51. Bollerslev J., Rosen T., Mollerup C.L., et al. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94(7):2255-2261.
52. Rubin M.R., Maurer M.S., McMahon D.J., et al. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90(6):3326-3330.
53. Walker M.D., Fleischer J., Rundek T., et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94(10):3849-3856.
54. Walker M.D., Fleischer J.B., Di Tullio M.R., et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2010, 95(5):2172-2179.
55. Iwata S., Walker M.D., Di Tullio M.R., et al. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2012, 97(1):132-137.
56. Walker M.D., Rundek T., Homma S., et al. Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. Eur J Endocrinol 2012, 167(2):277-285.
57. Khoo T.K., Vege S.S., Abu-Lebdeh H.S., et al. Acute pancreatitis in primary hyperparathyroidism: a population-based study. J Clin Endocrinol Metab 2009, 94(6):2115-2118.
58. Fitzpatrick L.A., Bilezikian J.P. Acute primary hyperparathyroidism. Am J Med 1987, 82:275-282.
59. Cusano N.E., Silverberg S.J., Bilezikian J.P. Normocalcemic primary hyperparathyroidism. J Clin Densitom 2013, 16:33-39.
60. Dowthwaite S.A., Young J.E., Pasternak J.D., Yoo J. Surgical management of primary hyperparathyroidism. J Clin Densitom 2013, 16:48-53.
61. Udelsman B.V., Udelsman R. Surgery in primary hyperparathyroidism: extensive personal experience. J Clin Densitom 2013, 16:54-59.
62. Rao D.S., Wilson R.J., Kleerekoper M., Parfitt A.M. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 1988, 67:1294-1298.
63. Silverberg S.J., Shane E., Jacobs T.P., et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999, 341:1249-1255.
64. Rubin M.R., Bilezikian J.P., McMahon D.J., et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008, 93(9):3462-3470.
65. National Institutes of Health Consensus development conference statement on primary hyperparathyroidism. J Bone Miner Res 1991, 6(Suppl 2):S9-S13.
66. Bilezikian J.P., Potts J.T., Fuleihan Gel.-H., et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 2002, 17(Suppl 2):N2-N11. J Clin Endocrinol Metab 87:5353-5361.
67. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary Statement from the Third International Workshop. J Clin Endocrinol Metab 2009, 94:335-339. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism.
68. Silverberg S.J., Locker F.G., Bilezikian J.P. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab 1996, 81(11):4007-4012.
69. Silverberg S.J., Brown I., Bilezikian J.P. Age as a criterion for surgery in primary hyperparathyroidism. Am J Med 2002, 113(8):681-684.
70. Locker F.G., Silverberg S.J., Bilezikian J.P. Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med 1997, 102(6):543-550.
71. Khan A., Grey A., Shoback D. Medical management of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009, 94:373-381.
72. Marcus R., Madvig P., Crim M., et al. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984, 100:633-640.
73. Grey A.B., Stapleton J.P., Evans M.C., et al. Effect of hormone replacement therapy on BMD in post-menopausal women with primary hyperparathyroidism. Ann Intern Med 1996, 125:360-368.
74. Rubin M.R., Lee K., Silverberg S.J. Raloxifene lowers serum calcium and markers of bone turnover in primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88(3):1174-1178.
75. Kahn A.A., Bilezikian J.P., Kung A., et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89(7):3319-3325.
76. Chow C.C., Chan W.B., Li J.K.Y., et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88(2):581-587.
77. Peacock M., Bilezikian J.P., Klassen P., et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90(1):135-141.
78. Peacock M., Bolognese M.A., Borofsky M., et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009, 94:4860-4867.
79. Peacock M., Bilezikian J.P., Bolognese M.A., et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 2011, 96(1):E9-E18.
80. Wermers R.A., Khosla S., Atkinson E.J., et al. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med 1997, 126(6):433-440.
81. Wermers R.A., Khosla S., Atkinson E.J., et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006, 21(1):171-177.